Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 9/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186307 | 1.00 | MAPK1 (0.41) | MAPK1F10F2HPGDTSHR | |
| SCHEMBL664008 | 1.00 | MAPK1 (0.41) | MAPK1F10F2HPGDTSHR | |
| SCHEMBL10184506 | 0.86 | RXFP1 (0.42) | MAPK1F10F2HPGDTSHR | |
| SCHEMBL10184431 | 0.85 | PDE4A (0.36) | HPGDACACBDGAT1 | |
| SCHEMBL10184505 | 0.84 | HRH3 (0.43) | MAPK1F10F2DGAT1 | |
| SCHEMBL10186251 | 0.84 | F10 (0.42) | MAPK1F10F2DGAT1 | |
| SCHEMBL10186450 | 0.84 | ALDH1A1 (0.42) | TSHRDGAT1 | |
| SCHEMBL10184512 | 0.84 | UTS2R (0.47) | — | |
| SCHEMBL10185367 | 0.84 | PRSS12 (0.41) | F10 | |
| SCHEMBL10184541 | 0.82 | OPRM1 (0.37) | HPGDACACBDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | claimed |
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | MAPK1 2553/4885F10 3477/4885F2 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.